LogoCrystal's Coder Hub

H34.8111

26 min read

🧬 ICD-10 CM H34.8111 — Central Retinal Vein Occlusion, Right Eye, With Macular Edema

Billable Code Confirmed

ICD-10 CM H34.8111 is a fully specified, 7-character ICD-10-CM code valid for FY2026 and appropriate for inpatient facility billing. The code structure builds from H34 (retinal vascular occlusions) → H34.8 (other retinal vascular occlusions) → H34.81 (central retinal vein occlusion) → H34.811 (right eye laterality) → final character “1” denoting the active complication of macular edema. All seven characters are required for billable submission; parent codes H34.81 and H34.811 are non-billable headers that cannot be submitted on a claim.

Non-Billable Parent Codes

H34.81 — Central retinal vein occlusion is a 5-character non-billable header that lacks both laterality and complication specificity; submission will result in a claim rejection from Medicare and most commercial payers. H34.811 — Central retinal vein occlusion, right eye is a 6-character non-billable subcategory that captures laterality but still lacks the required 7th character specifying the complication (macular edema, retinal neovascularization, or stable); this code will trigger automated claim edits. H34 — Retinal vascular occlusions is the broadest non-billable category header, entirely too unspecified for inpatient or outpatient claim submission.

Clinical Context

Central retinal vein occlusion (CRVO) with macular edema is the most common vision-threatening manifestation of CRVO, causing fluid accumulation in the macula that directly reduces central visual acuity. The distinction between macular edema, retinal neovascularization, and a stable (resolved) occlusion drives ICD-10-CM 7th character selection and must be explicitly documented by the treating ophthalmologist. Macular edema in this context is confirmed on optical coherence tomography (OCT) and may drive urgent inpatient or outpatient anti-VEGF therapy, laser treatment, or intravitreal steroid implantation. Laterality documentation — right versus left — is mandatory and must be drawn from physician attestation, not assumed from procedural or radiology records.

Code Classification

ICD-10 CM H34.8111 is a diagnosis code within the ICD-10-CM classification system and is not a procedure code; it identifies the clinical condition rather than the service rendered. This code belongs to Chapter 7 — Diseases of the Eye and Adnexa (H00–H59) and represents a retinal vascular pathology, not a surgical or interventional procedure. Any procedures performed — intravitreal injection, laser photocoagulation, or intravitreal implant — require separately reported CPT codes for professional billing or ICD-10-PCS codes for inpatient facility reporting.

🔍 Code Description

Central retinal vein occlusion (CRVO) occurs when thrombus formation or external compression blocks the central retinal vein at or posterior to the lamina cribrosa, causing venous outflow obstruction and a resultant cascade of elevated intravascular hydrostatic pressure throughout the entire retinal venous system.1 This increased pressure drives extravasation of plasma, erythrocytes, and lipoproteins from capillary beds into the extracellular retinal space, most critically accumulating at the macula — the central retinal zone responsible for high-acuity and color vision. When this fluid accumulation is documented at the level of the H34.8111 diagnosis, the complication of macular edema is present, producing the characteristic central vision blur, metamorphopsia, and scotoma that define CRVO-related visual loss.2 Risk factors are predominantly systemic vascular — I10 (essential hypertension) is the most consistently documented driver, followed by hyperlipidemia (E78.5), open-angle glaucoma, and hypercoagulable states such as antiphospholipid syndrome; the underlying systemic condition must be coded as an additional diagnosis when documented by the treating physician.3

The clinical distinction between ischemic and non-ischemic CRVO is fundamental to prognosis and treatment escalation, even though ICD-10-CM does not yet differentiate these subtypes at a separate 7th character level.4 Ischemic CRVO — characterized by more than 10 disc areas of capillary non-perfusion on fluorescein angiography — carries substantially higher risk of anterior segment neovascularization, neovascular glaucoma, and permanent vision loss than non-ischemic (perfused) CRVO. Non-ischemic CRVO has a more favorable natural history but still requires close monitoring for conversion to ischemic disease and potential progression to H34.8112 when retinal neovascularization develops. In the inpatient setting, CRVO admissions most commonly arise when vision loss is acute and severe, when bilateral involvement is confirmed (H34.8131), or when the underlying systemic etiology — such as newly diagnosed malignant hypertension or hypercoagulable disorder — requires concurrent inpatient management and workup alongside the ocular treatment.5

🌳 Code Tree / Hierarchy

H34 — Retinal vascular occlusions ❌ Non-billable
│
├── H34.0 — Transient retinal artery occlusion ❌ Non-billable
│   ├── H34.00 — ...unspecified eye ✅ Billable
│   ├── H34.01 — ...right eye ✅ Billable
│   └── H34.02 — ...left eye ✅ Billable
│
├── H34.1 — Central retinal artery occlusion ❌ Non-billable
│   ├── H34.10 — ...unspecified eye ✅ Billable
│   ├── H34.11 — ...right eye ✅ Billable
│   └── H34.12 — ...left eye ✅ Billable
│
├── H34.8 — Other retinal vascular occlusions ❌ Non-billable
│   │
│   ├── H34.81 — Central retinal vein occlusion ❌ Non-billable
│   │   │
│   │   ├── H34.811 — ...right eye ❌ Non-billable
│   │   │   ├── H34.8110 — ...right eye, unspecified ✅ Billable
│   │   │   ├── H34.8111 — ...right eye, with macular edema ◀ THIS CODE ✅ Billable
│   │   │   ├── H34.8112 — ...right eye, with retinal neovascularization ✅ Billable
│   │   │   └── H34.8119 — ...right eye, stable ✅ Billable
│   │   │
│   │   ├── H34.812 — ...left eye ❌ Non-billable
│   │   │   ├── H34.8120 — ...left eye, unspecified ✅ Billable
│   │   │   ├── H34.8121 — ...left eye, with macular edema ✅ Billable
│   │   │   ├── H34.8122 — ...left eye, with retinal neovascularization ✅ Billable
│   │   │   └── H34.8129 — ...left eye, stable ✅ Billable
│   │   │
│   │   └── H34.813 — ...bilateral ❌ Non-billable
│   │       ├── H34.8130 — ...bilateral, unspecified ✅ Billable
│   │       ├── H34.8131 — ...bilateral, with macular edema ✅ Billable
│   │       ├── H34.8132 — ...bilateral, with retinal neovascularization ✅ Billable
│   │       └── H34.8139 — ...bilateral, stable ✅ Billable
│   │
│   └── H34.83 — Tributary (branch) retinal vein occlusion ❌ Non-billable
│       └── H34.831 — ...right eye ❌ Non-billable
│           ├── H34.8311 — ...right eye, with macular edema ✅ Billable
│           └── H34.8312 — ...right eye, with retinal neovascularization ✅ Billable
│
└── H34.9 — Retinal vascular occlusion, unspecified ✅ Billable

Macular Edema Must Be Explicitly Documented by the Treating Physician

Do not assign the macular edema 7th character (H34.8111) based solely on OCT findings referenced in a radiology or ancillary report — the treating physician must document the diagnosis of macular edema associated with CRVO in their attestation or progress note. If the ophthalmologist documents only “CRVO” without specifying the complication, query for clarification before defaulting to H34.8110 (unspecified) or H34.8111.

Tip

The 7th character in the H34.81x series describes the current clinical state of the occlusion, not its history. A patient with a previously documented CRVO who now has a stable, resolved state should be coded to H34.8119 (stable), not H34.8111, even if macular edema was present at initial presentation. Physicians should explicitly document active versus resolved status at each encounter to support accurate 7th character selection.

✅ Includes

  • Central retinal vein occlusion with cystoid macular edema (CME), right eye: CME is the most common type of macular edema in CRVO, referring to fluid accumulation in cyst-like spaces within the outer plexiform and inner nuclear layers; when the physician documents CME, H34.8111 is appropriate. Confirm laterality explicitly from physician attestation before assignment.

  • CRVO right eye with macular thickening: Macular thickening on OCT documented as clinically significant by the treating ophthalmologist maps to this code when attributed to CRVO, as the code encompasses the edematous complication regardless of whether the specific term “cystoid” appears in the note.

  • Ischemic CRVO with macular edema, right eye: ICD-10-CM does not distinguish between ischemic and non-ischemic CRVO at a separate code level; both subtypes map to H34.8111 when macular edema is documented. CDI should query for ischemic versus non-ischemic classification for clinical completeness even if code assignment is unchanged.

  • Non-ischemic CRVO with macular edema, right eye: Non-ischemic (perfused) CRVO with concurrent macular edema is fully captured by H34.8111; the code itself does not imply ischemic pathology and is appropriate regardless of perfusion status on fluorescein angiography.

  • Acute CRVO with subretinal fluid and macular edema, right eye: When the physician documents subretinal fluid in addition to intraretinal edema in the setting of CRVO, H34.8111 remains appropriate; the distinction between intraretinal and subretinal fluid is clinical and does not produce a separate ICD-10-CM entity at this time.

❌ Excludes

Excludes 1

Danger

The most common Excludes 1 error for this code family is conflating transient vision loss (amaurosis fugax, G45.3) with an established, confirmed retinal vein occlusion on the same encounter. Amaurosis fugax represents a TIA-equivalent with transient monocular vision loss that typically resolves without retinal infarction and cannot be reported simultaneously with H34.8111. Coders who see an ophthalmology consult documenting “transient vision loss later confirmed as CRVO” must verify the final attending diagnosis before code assignment — do not report both at the same encounter.

G45.3 — Amaurosis fugax: This code represents transient ischemic monocular vision loss and is mutually exclusive with H34.8111 at the Excludes 1 level, meaning both codes cannot be reported for the same eye at the same encounter. The distinction hinges on whether vision loss was transient and self-resolving (G45.3) versus an established vascular occlusion with a persistent macular complication (H34.8111). If the clinical record references both conditions at separate time points, review the encounter context carefully and query the attending before dual-reporting.

H34.11 — Central retinal artery occlusion, right eye: Arterial and venous occlusions of the central retinal vasculature are clinically distinct diagnoses and are mutually exclusive at the same site and same encounter. Central retinal artery occlusion (CRAO) involves the arterial supply and presents as sudden, profound monocular vision loss with a pale, infarcted retina, whereas CRVO involves venous outflow with a hemorrhagic, tortuous retinal appearance. When operative or consult notes are ambiguous about arterial versus venous involvement, query the ophthalmologist before finalizing code selection.

Excludes 2

H35.81 — Retinal edema: H35.81 represents retinal edema attributed to causes other than the current vascular occlusion and may be reported as an additional code when documented as a separately identified clinical finding distinct from the occlusion-associated macular edema. In practice, the macular edema in CRVO is already captured within the 7th character of H34.8111; H35.81 should only be added when the physician explicitly documents a concurrent retinal edema process from a distinct etiology (e.g., radiation retinopathy or diabetic retinopathy) affecting the same eye. Query the ophthalmologist if documentation is ambiguous about whether a single or dual etiology is driving the edema.

📋 Clinical Overview

CRVO Complication Classification and 7th Character Selection

Central retinal vein occlusion is the second most common retinal vascular disorder after diabetic retinopathy, with an estimated global prevalence of approximately 0.8% in adults over 40.1 The ICD-10-CM 7th character system for H34.81 mirrors the clinical staging of disease activity, distinguishing active complications — macular edema and retinal neovascularization — from a stable, resolved state, which has direct implications for ongoing treatment authorization, prior authorization approvals, and clinical management intensity.

FeatureH34.8111H34.8112H34.8119
Active ComplicationMacular edema — fluid accumulation at the foveal center confirmed on OCT with central subfield thickness typically >300 µm; directly reduces central visual acuityRetinal neovascularization — abnormal new vessel growth driven by ischemia-related VEGF upregulation; increases risk of vitreous hemorrhage and neovascular glaucomaStable (old) occlusion — no active macular edema or neovascularization; vessels may show collateral sheathing or optociliary shunts on fundoscopy
Primary TreatmentIntravitreal anti-VEGF agents (aflibercept, ranibizumab, bevacizumab) or intravitreal dexamethasone implant; grid laser photocoagulation in refractory casesPanretinal photocoagulation (PRP) to ablate ischemic retina and suppress VEGF stimulus; anti-VEGF adjunct therapy is common in neovascular casesObservation and systemic risk factor management; periodic OCT and fundus examination for recurrence or late conversion
Vision PrognosisVariable; strongly correlated with foveal involvement and baseline visual acuity; early anti-VEGF intervention improves outcomes in non-ischemic casesGuarded; high risk of progression to vitreous hemorrhage or neovascular glaucoma if neovascularization is not promptly treatedGenerally stable; natural history studies suggest spontaneous resolution in a subset of non-ischemic cases, but conversion to ischemic CRVO remains a long-term risk
Inpatient TriggerAcute severe central vision loss with concurrent hypertensive crisis, bilateral involvement, or urgent systemic workup for underlying etiologyAdvanced ischemic CRVO with vitreous hemorrhage or early neovascular glaucoma requiring urgent interventionRarely triggers inpatient admission; stable CRVO without active complication is typically managed in the outpatient ophthalmology setting

Important

When the ophthalmology consult documents both macular edema and retinal neovascularization concurrently in the same eye, query whether both processes are independently documented — ICD-10-CM does not currently offer a single code capturing both complications simultaneously. Code the most clinically significant complication or query the attending for guidance on which condition is the primary driver of the admission or encounter.

Manifestations & Symptom Burden

  • Decreased central visual acuity: The most common presenting symptom, ranging from mild blur to near-total central field loss, directly caused by fluid displacement of foveal photoreceptors; severity correlates with central subfield thickness on OCT and is often the primary functional complaint driving inpatient evaluation.

  • Metamorphopsia: Visual distortion causing straight lines to appear wavy or bent, resulting from displacement of photoreceptors by sub- or intraretinal fluid; frequently detected on Amsler grid testing and should be documented by the treating ophthalmologist to support clinical severity.

  • Central or paracentral scotoma: A defined area of absent or severely reduced vision corresponding to areas of greatest retinal thickening; documents the functional impact of macular edema beyond visual acuity measurement alone.

  • Dilated, tortuous retinal veins in all four quadrants: A fundoscopic finding distinguishing CRVO from branch RVO — in CRVO all four quadrants are involved; documents the extent of venous outflow obstruction and supports the central versus tributary distinction critical for code selection.

  • Flame-shaped retinal hemorrhages: Superficial hemorrhages in a nerve fiber layer distribution visible on fundoscopy and fluorescein angiography, spanning all four retinal quadrants in CRVO; should be documented by the treating ophthalmologist and supports the diagnosis when the clinical picture is otherwise ambiguous.

Tip

Manifestations such as dilated tortuous veins, retinal hemorrhages, and disc edema are part of the clinical presentation of H34.8111 and do not require separately coded ICD-10-CM entries unless the physician explicitly identifies them as distinct diagnoses requiring independent management. Disc edema in the setting of CRVO does not independently require an H47.xx code unless the physician documents optic disc edema as a clinically separate problem. Coders should never append manifestation codes that are not explicitly attributed by the attending physician in the current encounter documentation.

💰 HCC Risk Adjustment

AttributeDetail
CMS-HCC v28 MappingNot mapped — H34.8111 has no assigned HCC category
RAF Score Contribution0.000 — No RAF weight assigned
RAPS Capture RequiredNo — condition does not require annual recapture for risk adjustment purposes
Comorbidity HCC OpportunitiesE11.39 (T2DM with other diabetic ophthalmic complication) — HCC 37 v28 if documented; E11.65 (T2DM with hyperglycemia) — HCC 37 v28 potential
Payer ImpactUHC, Cigna, Aetna may require clinical documentation linking macular edema to the CRVO event for anti-VEGF authorization; HCC gap tools will not flag this code for recapture

ICD-10 CM H34.8111 does not contribute to risk-adjusted payment under Medicare Advantage CMS-HCC v28 or equivalent commercial RAF models, as retinal vein occlusions are not included in the hierarchical condition categories for vascular or ophthalmic disease at this time.3 However, the presence of H34.8111 in the record serves as a clinical flag that risk-relevant comorbidities — particularly hypertension, diabetes mellitus, and hyperlipidemia — should be present and coded to full specificity as additional diagnoses. CDI programs should treat CRVO encounters as an opportunity to capture secondary diagnoses that carry HCC weight, such as type 2 diabetes mellitus with ophthalmic complications (E11.39) when documented by the treating physician. Failure to separately code contributing systemic conditions means that a clinically complex patient’s risk score may not accurately reflect their true burden of illness, leading to potential underpayment in capitated models. Annual CDI audit of ophthalmology encounters should include a specific check for undercoded systemic vascular comorbidities with HCC relevance.

🏥 MS-DRG Assignment

DRGTitleEst. Weight (v41)GMLOS
DRG 124Other Disorders of the Eye with MCC~1.5–1.8~3.8 days
DRG 125Other Disorders of the Eye with CC~0.9–1.1~2.4 days
DRG 126Other Disorders of the Eye without CC/MCC~0.6–0.8~1.7 days

ICD-10 CM H34.8111 as the principal diagnosis maps to MDC 02 — Diseases and Disorders of the Eye, with DRG assignment (124 vs. 125 vs. 126) determined entirely by whether secondary diagnoses meet CC or MCC threshold under MS-DRG v41 definitions.5 The macular edema inherent to H34.8111 itself does not confer CC or MCC status — DRG elevation requires separately documented and coded comorbidities such as hypertensive crisis (I16.0), acute heart failure (I50.9), or sepsis. Coders should review the entire record for secondary diagnoses under active management during the admission — particularly systemic conditions appearing in nursing notes, medication reconciliation, or ancillary reports but absent from the physician’s problem list — and initiate CDI query when indicated. A frequent revenue integrity gap in ophthalmology inpatient encounters is failing to code the patient’s glaucoma, diabetes, or hypertension as additional diagnoses when they are clearly being managed during the same inpatient stay. Sequencing H34.8111 as the principal diagnosis is appropriate when the reason for admission after study was the evaluation and treatment of CRVO with macular edema; if the admission was primarily driven by an underlying condition such as a hypercoagulable disorder, principal diagnosis sequencing should be reconsidered with the attending physician.

🔗 Related ICD-10 CM Codes

Central Retinal Vein Occlusion Variants — Same Subcategory:

  • H34.8112 — Central retinal vein occlusion, right eye, with retinal neovascularization — represents disease progression beyond macular edema into ischemia-driven neovascular proliferation; report when neovascularization is the active documented complication
  • H34.8121 — Central retinal vein occlusion, left eye, with macular edema — contralateral eye equivalent; report if bilateral involvement exists but only the left eye has macular edema
  • H34.8131 — Central retinal vein occlusion, bilateral, with **macular edem**a — bilateral simultaneous CRVO, a rare but recognized presentation strongly associated with hypercoagulable states or systemic vasculopathy
  • H34.8119 — Central retinal vein occlusion, right eye, stable — appropriate for follow-up encounters once the acute complication has resolved and the occlusion is inactive per physician documentation

Related Retinal Vascular and Systemic Codes:

  • H34.8311 — Tributary (branch) retinal vein occlusion, right eye, with macular edema — branch RVO affects only one quadrant versus all four in CRVO; a critical distinction that must be driven by physician documentation
  • I10 — Essential (primary) hypertension — the most common systemic risk factor for CRVO; must be coded as an additional diagnosis when documented as active and under management during the inpatient stay
  • E78.5 — Hyperlipidemia, unspecified — a frequently contributing vascular risk factor; should be reported when listed as an active problem on the physician’s documentation
  • E11.39 — Type 2 diabetes mellitus with other diabetic ophthalmic complication — report when diabetes is documented as contributing to the retinal vascular disease; do not add diabetic retinopathy codes without explicit physician attribution

🛠️ Commonly Associated CPT Codes

  • 67028 — Intravitreal injection of pharmacologic agent: The primary outpatient procedure for CRVO-related macular edema, covering intravitreal ranibizumab (Lucentis), aflibercept (Eylea), bevacizumab (Avastin), or dexamethasone implant (Ozurdex); supports medical necessity when paired with H34.8111 as the diagnosis. Report separately per eye per session; NCCI edits may bundle multiple injections administered to the same eye on the same date without modifier justification.

  • 92134 — Scanning computerized ophthalmic diagnostic imaging, posterior segment (OCT): Essential for confirming and quantifying macular edema in CRVO; the central subfield thickness measurement drives anti-VEGF re-injection protocols and treatment decisions. Billable per eye per session; documentation must include the physician’s interpretation and report — a technician-generated OCT printout alone does not satisfy this requirement.

  • 92235 — Fluorescein angiography with interpretation and report: Used to classify CRVO as ischemic vs. non-ischemic, identify areas of capillary non-perfusion, and detect early neovascularization; supports medical necessity for aggressive anti-VEGF or panretinal laser treatment. Requires a separate, independently documented physician interpretation and is typically performed at diagnosis and selectively thereafter.

  • 92250 — Fundus photography with interpretation and report: Documents the funduscopic appearance of CRVO including hemorrhages, disc edema, and vascular tortuosity for baseline documentation and treatment response monitoring. Billable separately from 92134 or 92235 when performed at the same session only when each study is independently medically necessary and separately documented by the physician.

  • 67228 — Treatment of extensive or progressive retinopathy, one or more sessions (panretinal photocoagulation): Indicated for ischemic CRVO with documented retinal neovascularization to reduce VEGF stimulus and prevent progression to neovascular glaucoma; less commonly paired with H34.8111 and more naturally reported with H34.8112. When billed alongside H34.8111, payers may require documentation that the case is progressing toward neovascularization risk or that PRP is being performed prophylactically per the treating ophthalmologist’s documented clinical judgment.

NCCI Bundling Considerations

When 67028 (intravitreal injection) is reported alongside 92134 (OCT) or 92235 (fluorescein angiography) on the same date of service, NCCI edits generally permit reporting all services if each is independently documented and medically necessary, as OCT and FA are diagnostic studies that inform the clinical decision driving the injection.6 However, 92250 (fundus photography) and 92134 (OCT) are frequently bundled by commercial payers — including BCBS of WI and UHC — when performed on the same date; review payer-specific LCD or NCD policies and ensure each study has a distinct, documented medical necessity rationale. The dexamethasone implant (Ozurdex) requires HCPCS J7312 in addition to 67028 for the injection technique; confirm payer coverage as some Wisconsin Medicaid plans require prior authorization for implant-based steroid therapy in CRVO and may have a separate HCPCS reporting requirement.

🔬 ICD-10-PCS Crosswalk

  • 3E0C3MZ — Introduction of Monoclonal Antibody into Eye, Percutaneous Approach: Used for inpatient intravitreal injection of anti-VEGF monoclonal antibody agents (e.g., ranibizumab, aflibercept) administered during an inpatient stay; the percutaneous approach (character 3) reflects the intravitreal needle technique. Confirm the specific substance character against the current FY2026 PCS Section 3 (Administration), Body System E, Operation 0, Body Part C (Eye) table before final code submission.

  • 3E0C3RZ — Introduction of Other Therapeutic Substance into Eye, Percutaneous Approach: Reported for inpatient administration of intravitreal dexamethasone implant (Ozurdex) or triamcinolone acetonide when performed for CRVO-related macular edema refractory to anti-VEGF therapy; substance differentiation between monoclonal antibody (MZ) and other therapeutic substance (RZ) is critical for accurate PCS root operation mapping. Verify the exact substance character against FY2026 PCS tables to avoid character-level inaccuracies on the facility claim.

  • 085K3ZZ — Destruction, Retina, Right, Percutaneous Approach (laser photocoagulation): The Destruction root operation is used in ICD-10-PCS when laser photocoagulation ablates retinal tissue — such as grid laser for macular edema or focal laser for branch vessel leakage; confirm that the surgeon’s documentation supports “destruction” of tissue as the operative intent versus a different root operation. Right retina body part character (K) must be confirmed against the FY2026 Eye body system table.

  • B20YZZZ — Imaging, Eye, Other Imaging (inpatient diagnostic OCT): May be reported when formal OCT is performed as a distinct inpatient diagnostic imaging service; confirm the modality character from the FY2026 PCS Imaging Section (B), Body System 2 (Eye) table, as specific posterior segment OCT coding in PCS may vary by facility policy and payer contract. Always verify ICD-10-PCS assignments against the current FY2026 tabular before submission.

💊 Coding Scenarios and Examples

Scenario 1: Acute CRVO with Macular Edema — Concurrent Hypertensive Urgency

A 67-year-old male with known hypertension presents to the ED with sudden onset blurred central vision in the right eye upon waking. Ophthalmology consult confirms central retinal vein occlusion right eye with significant macular edema on OCT (CST 487 µm). The admitting physician documents hypertensive urgency requiring IV labetalol titration. Fluorescein angiography confirms non-ischemic CRVO. Intravitreal aflibercept is administered at the bedside.

Correct Coding:

  • H34.8111 — Central retinal vein occlusion, right eye, with macular edema (principal diagnosis)
  • I16.0 — Hypertensive urgency (CC — elevates to DRG 125)
  • I10 — Essential hypertension (underlying chronic condition, active)
  • E78.5 — Hyperlipidemia (documented on medication reconciliation, active)

Sequencing: H34.8111 sequences as principal because the reason for admission after study was the evaluation and initiation of treatment for CRVO with macular edema; the hypertensive urgency is a significant secondary condition meeting CC threshold and should not be omitted.

CDI Note: Query the ophthalmologist to confirm ischemic versus non-ischemic CRVO classification. Query the admitting physician to establish whether the hypertensive urgency was a precipitating event for the occlusion or an independently identified problem — this distinction affects CDI documentation quality even if code assignment does not change.

Scenario 2: Bilateral CRVO — Newly Diagnosed Antiphospholipid Syndrome

A 44-year-old female is admitted for bilateral CRVO with macular edema discovered on ophthalmology consult during an inpatient hematology admission for newly diagnosed antiphospholipid syndrome. Right eye CST is 512 µm; left eye CST is 344 µm; macular edema is present bilaterally per the attending ophthalmologist’s note. Hematology initiates anticoagulation therapy.

Correct Coding:

  • H34.8131 — Central retinal vein occlusion, bilateral, with macular edema (principal or secondary — see note)
  • D68.61 — Antiphospholipid syndrome (underlying hematologic etiology)
  • Z79.01 — Long-term (current) use of anticoagulants (newly initiated)

Sequencing: If the reason for admission was the CRVO bilateral workup and treatment, H34.8131 may be principal. If the antiphospholipid syndrome admission and anticoagulation initiation was the primary driver, D68.61 sequences as principal. Query the attending physician for clarification on reason for admission after study before finalizing principal diagnosis.

CDI Note: Bilateral CRVO in a patient under 50 is a strong clinical indicator of hypercoagulable disease. Confirm that the hematologic diagnosis is explicitly documented and linked to the CRVO by the treating physicians, as this connection supports clinical and coding accuracy for both diagnoses.

Scenario 3: Follow-Up Readmission — Macular Edema Resolved, Now Stable

A 71-year-old female is readmitted for right eye evaluation following prior treatment for CRVO with macular edema. OCT on this admission shows complete resolution of macular edema (CST 241 µm, within normal limits). The treating ophthalmologist documents: “Central retinal vein occlusion, right eye — stable, no active macular edema at this time. No further injection indicated.”

Correct Coding:

  • H34.8119 — Central retinal vein occlusion, right eye, stable (principal — macular edema resolved per physician documentation)
  • I10 — Essential hypertension (active comorbidity under management)

Sequencing: Once the physician documents stability and resolution of macular edema in the current encounter, the correct 7th character shifts from “1” (macular edema) to “9” (stable). Carrying H34.8111 forward from a prior encounter when the current note documents resolution is a coding error.

CDI Note: This scenario illustrates the encounter-specific nature of the 7th character. Never default to a prior encounter’s diagnosis code without confirming the current clinical status in the present admission documentation.

⚠️ Coding Pitfalls and Tips

  1. Do not carry H34.8111 forward once macular edema resolves. The 7th character is encounter-specific and reflects the current clinical state, not historical complication history. A patient with previously documented macular edema who presents with a current note documenting stable CRVO without active edema should be assigned H34.8119, not H34.8111. Perpetuating the macular edema code beyond resolution misrepresents the patient’s current clinical status and may generate improper medical necessity justification for treatments no longer being administered.

  2. Laterality errors are the most frequent automated claim edit for this code family. H34.8111 is right eye only; left eye CRVO with macular edema codes to H34.8121, and bilateral presentation codes to H34.8131. Laterality must always be drawn from the treating physician’s documentation — do not infer from procedural records, OR reports, or nursing notes without physician attestation. Medicare and Wisconsin Medicaid both run automated laterality edits on ophthalmology inpatient claims, making this a predictable audit target.

  3. Do not conflate CRVO (H34.8111) with branch retinal vein occlusion (H34.8311). CRVO involves the central retinal vein with four-quadrant retinal involvement, while tributary branch RVO involves one quadrant supplied by a single tributary vessel. The distinction is fundoscopic and must be explicitly documented by the treating ophthalmologist; coders should query when the note reads “retinal vein occlusion” without specifying central versus branch. Miscoding between these entities affects clinical data integrity, DRG accuracy, and prior authorization approvals for anti-VEGF protocols.

  4. Macular edema from CRVO does not justify adding H35.81 as a secondary code in most cases. The complication is already captured within the 7th character of H34.8111; appending H35.81 is duplicative unless the physician explicitly documents a separate retinal edema process from a distinct etiology affecting the same eye. Over-appending retinal edema as a secondary diagnosis may trigger NCCI or clinical edit flags and creates a documentation discrepancy that complicates payer review.

  5. Failing to code the underlying systemic etiology is a CDI gap that affects both risk profiling and DRG accuracy. CRVO is rarely idiopathic — I10, E78.5, and diabetes are the most common contributors and must be coded as additional diagnoses when documented as active. Missing these secondary diagnoses suppresses potential CC/MCC capture if those conditions independently meet threshold, and leaves genuine clinical complexity underdocumented in the facility record. A CDI query should be initiated any time the record supports a contributing systemic condition not listed on the physician’s active problem list or discharge summary.

  6. Verify that CRVO documentation supports H34.8111 and not a diabetic retinopathy-related macular edema code. Diabetic patients with retinal vascular disease may have both diabetic retinopathy and CRVO; the physician must explicitly attribute the macular edema to the vein occlusion — not to diabetic retinopathy — for H34.8111 to be appropriate. When the attending documents “diabetic macular edema” and separately notes a retinal vein occlusion without clear attribution, query the ophthalmologist before assigning either code as the primary retinal diagnosis. Dual reporting without physician attribution is a documented audit risk in ophthalmology inpatient coding.

📚 Sources

1. National Center for Health Statistics (NCHS). *ICD-10-CM Official Tabular List of Diseases and Injuries, FY2026.* U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. https://www.cdc.gov/nchs/icd/icd-10-cm.htm 2. American Academy of Ophthalmology (AAO). *Retinal Vein Occlusions Preferred Practice Pattern.* AAO; 2022. https://www.aao.org/preferred-practice-pattern/retinal-vein-occlusions-ppp 3. Rogers S, McIntosh RL, Cheung N, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. *Ophthalmology.* 2010;117(2):313-319.e1. doi:10.1016/j.ophtha.2009.07.017 4. Hayreh SS. Ocular vascular occlusive disorders: natural history of visual outcome. *Progress in Retinal and Eye Research.* 2014;41:1-25. doi:10.1016/j.preteyeres.2014.04.001 5. Centers for Medicare & Medicaid Services (CMS). *MS-DRG Definitions Manual, Version 41.* CMS; FY2024. https://www.cms.gov/medicare/payment/prospective-payment-systems/acute-inpatient-pps/ms-drg-classifications-and-software 6. Centers for Medicare & Medicaid Services (CMS). *ICD-10-CM Official Guidelines for Coding and Reporting, FY2026.* CMS and NCHS. https://www.cms.gov/files/document/fy-2026-icd-10-cm-coding-guidelines.pdf 7. American Hospital Association (AHA). *Coding Clinic for ICD-10-CM/PCS.* Various issues. American Hospital Association Press. 8. AAPC. *CIC (Certified Inpatient Coder) Exam Preparation Reference Manual.* AAPC; 2025.

Graph View

Recent Notes